Open an account

Septerna

SEPN · NASDAQ

$39.35+$2.97 (+8.16%)TodayMarket closed ·
Prev close $36.38

About SEPN

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 130 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Employees
130
Headquarters
South San Francisco, California
Listed
Oct 25, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
septerna.com

SEPN key statistics

Market cap
1.84B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
419.58K
Volume
418.33K
Open price
$36.46
High today
$39.55
Low today
$36.25
52 Week high
$51.10
52 Week low
$17.55

Septerna (SEPN) at a glance

As of Oct 20, 2026, Septerna (SEPN) shares are priced at $39.35, giving the company a market cap of 1.84B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $36.25 and $39.55. The current price is 8.6% above the day's low and 0.5% below its high.

Volume so far is 418.33K shares, in line with the average of 419.58K shares a day.

Over the past year Septerna has ranged from $17.55 to $51.10, and now sits 65% of the way up that range.

Septerna met or beat analyst EPS estimates in 4 of the last 7 quarters. In Q2 FY26 it reported -$0.29 per share against an estimate of -$0.4345.

The average analyst price target is $56.10, 42.6% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $56.10
Low
$49.49
Now
$39.35
High
$65.10

SEPN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 7 quarters, by 26.3% on average.

  1. Q4 FY24: reported -$0.64 per share against an estimate of -$0.7072
  2. Q1 FY25: reported -$0.49 per share against an estimate of -$0.4565
  3. Q2 FY25: reported -$0.56 per share against an estimate of $0.8772
  4. Q3 FY25: reported -$0.09 per share against an estimate of $0.8099
  5. Q4 FY25: reported -$0.24 per share against an estimate of -$0.2588
  6. Q1 FY26: reported -$0.19 per share against an estimate of -$0.425
  7. Q2 FY26: reported -$0.29 per share against an estimate of -$0.4345

SEPN news

  • Press releaseBusiness Wire

    Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

  • Press releaseGlobe Newswire

    Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

  • Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

  • The Analyst Verdict: Septerna In The Eyes Of 6 Experts

  • Avi Kapoor

    This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

  • Press releaseGlobe Newswire

    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

  • Vandana Singh

    Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

Similar companies

Companies in the same industry as Septerna

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.